Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

1.

Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus.

Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, Hirsch MS, Walker BD.

Clin Infect Dis. 2003 Dec 15;37(12):1693-8. Epub 2003 Nov 17.

PMID:
14689353
[PubMed - indexed for MEDLINE]
Free Article
2.

Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.

Quiñones-Mateu ME, Tadele M, Parera M, Mas A, Weber J, Rangel HR, Chakraborty B, Clotet B, Domingo E, Menéndez-Arias L, Martínez MA.

J Virol. 2002 Oct;76(20):10546-52.

PMID:
12239335
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
[PubMed - indexed for MEDLINE]
4.

HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.

Izopet J, Marchou B, Charreau I, Sauné K, Tangre P, Molina JM, Aboulker JP; Window (ANRS 106) Study Team.

Antivir Ther. 2008;13(4):537-45.

PMID:
18672532
[PubMed - indexed for MEDLINE]
5.

Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.

van Maarseveen NM, Wensing AM, de Jong D, Taconis M, Borleffs JC, Boucher CA, Nijhuis M.

J Infect Dis. 2007 Feb 1;195(3):399-409. Epub 2006 Dec 29.

PMID:
17205479
[PubMed - indexed for MEDLINE]
Free Article
6.

In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.

Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, Petropoulos CJ, Deeks SG, Kuritzkes DR.

J Virol. 2009 Feb;83(4):2038-43. doi: 10.1128/JVI.02154-08. Epub 2008 Nov 19.

PMID:
19019971
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z.

Antimicrob Agents Chemother. 2006 Aug;50(8):2772-81.

PMID:
16870771
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.

Mathiesen S, Dam E, Roge B, Joergensen LB, Laursen AL, Gerstoft J, Clavel F.

Antivir Ther. 2007;12(3):335-43.

PMID:
17591023
[PubMed - indexed for MEDLINE]
9.

An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs.

van Maarseveen NM, de Jong D, Boucher CA, Nijhuis M.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):162-8.

PMID:
16645546
[PubMed - indexed for MEDLINE]
10.

HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.

Prado JG, Parkin NT, Clotet B, Ruiz L, Martinez-Picado J.

Clin Infect Dis. 2005 Sep 1;41(5):729-37. Epub 2005 Jul 22.

PMID:
16080097
[PubMed - indexed for MEDLINE]
Free Article
11.

Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission.

Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, Krivine A, Compagnucci A, Katlama C, Girard PM, Calvez V.

Antivir Ther. 2004 Jun;9(3):415-21.

PMID:
15259904
[PubMed - indexed for MEDLINE]
12.

Novel drug resistance mutations in HIV: recognition and clinical relevance.

Perno CF, Svicher V, Ceccherini-Silberstein F.

AIDS Rev. 2006 Oct-Dec;8(4):179-90. Review.

PMID:
17219733
[PubMed - indexed for MEDLINE]
13.

High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.

Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, Petropoulos C, Whalen CC, Kyeyune F, Atwine D, Kityo C, Mugyenyi P, Arts EJ.

AIDS Res Hum Retroviruses. 2004 Apr;20(4):355-64.

PMID:
15157354
[PubMed - indexed for MEDLINE]
14.

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR.

Clin Infect Dis. 2005 Jul 15;41(2):236-42. Epub 2005 Jun 7.

PMID:
15983922
[PubMed - indexed for MEDLINE]
Free Article
15.
16.

The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Cong ME, Heneine W, García-Lerma JG.

J Virol. 2007 Mar;81(6):3037-41. Epub 2006 Dec 27.

PMID:
17192300
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.

Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RS, Chequer-Fernandez SL, Oliveira SM, Arakaki-Sanchez D, Chequer PJ, Morgado MG.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):73-8. Epub 2005 Apr 12.

PMID:
15867968
[PubMed - indexed for MEDLINE]
Free Article
18.

Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.

Diallo K, Oliveira M, Moisi D, Brenner B, Wainberg MA, Götte M.

Antimicrob Agents Chemother. 2002 Jul;46(7):2254-6.

PMID:
12069983
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment-naive and treatment-experienced patients from Pune, India.

Sen S, Tripathy SP, Chimanpure VM, Patil AA, Bagul RD, Paranjape RS.

AIDS Res Hum Retroviruses. 2007 Apr;23(4):489-97.

PMID:
17506605
[PubMed - indexed for MEDLINE]
20.

Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes.

de Mendoza C, Rodriguez C, Corral A, del Romero J, Gallego O, Soriano V.

Clin Infect Dis. 2004 Oct 15;39(8):1231-8. Epub 2004 Sep 27.

PMID:
15486849
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk